In the wake of the increase in Current Liabilities in the third quarter 2026, Quick Ratio fell to 4.4 below Veracyte Inc average.

Within Medical Laboratories industry 5 other companies have achieved higher Quick Ratio than Veracyte Inc in third quarter 2026. While Quick Ratio total ranking has improved so far during the Q3 2026 to 508, from total ranking in the second quarter 2026 at 617.

Explain Quick Ratio?
How much Cash & cash equivalents VCYT�s has?
What are VCYT�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/VCYT/financial-strength

https://api.csimarket.com/api/v1/companies/VCYT/fundamentals

https://api.csimarket.com/api/v1/companies/VCYT/fundamentals?mode=as_of&as_of=YYYY-MM-DD

Programmatic access for models, analytics, and integration workflows.

Explore the Financial Data API

Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery

Connect Your AI Assistant

How to Connect Your AI Assistant to CSIMarket MCP MCP Server

Access this full dataset via API

Free sample Full docs All endpoints

VCYT Quick Ratio	(Sep 30 2026) Q3	(Jun 30 2026) Q2	(Mar 31 2026) Q1	(Dec 31 2025) Q4	(Sep 30 2025) Q3
Y / Y Current Liabilities Change	24.84 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent Change	17.42 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio MRQ	4.4	Subscribe	Subscribe	Subscribe	Subscribe
VCYT's Total Ranking	# 508	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities Change	34.23 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent Change	-23.92 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick Ratio third quarter 2026 Company Ranking
Within:	No.
Medical Laboratories Industry	# 6
Healthcare Sector	# 212
Overall Market	# 508

Quick Ratio Statistics
High	Average	Low
27.88	5.61	1.23
(Sep 30 2020)		(Sep 30 2013)

Financial Statements
Veracyte Inc 's Current Liabilities	$ 84 Millions	Visit VCYT's Balance sheet
Veracyte Inc 's Cash & cash equivalent	$ 371 Millions	Visit VCYT's Balance sheet
Source of VCYT's Sales		Visit VCYT's Sales by Geography

Cumulative Veracyte Inc 's Quick Ratio

VCYT's Quick Ratio for the trailling 12 Months

VCYT Quick Ratio	(Sep 30 2026) 12 Months	(Jun 30 2026) 12 Months	(Mar 31 2026) 12 Months	(Dec 31 2025) 12 Months	(Sep 30 2025) 12 Months
Y / Y Current Liabilities TTM Growth	-6.92 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent TTM Growth	54.46 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio TTM	5.87	Subscribe	Subscribe	Subscribe	Subscribe
Total Ranking TTM	# 350	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities TTM Growth	7.1 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent TTM Growth	3.85 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick ratio ranking by company, industry and sector >> Back to VCYT Financial Strength Comparisons >> Go to Compare VCYT Quick Ratio to its Competitors

On the trailing twelve months basis Due to growth in Current Liabilities in the Q3 2026 to $84.21 millions, cumulative Quick Ratio decreased to 5.87 above the VCYT average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Medical Laboratories industry 32 other companies have achieved higher Quick Ratio than Veracyte Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2026 from 2949 to 3616.

Explain Quick Ratio?
How much Cash & cash equivalents VCYT�s has?
What are VCYT�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Medical Laboratories Industry	# 33
Healthcare Sector	# 860
Within the Market	#

trailing twelve months Quick Ratio Statistics
High	Average	Low
15.79	5.05	2.46
(Dec 31 2020)		(Mar 31 2015)

Companies with similar Quick Ratio in the quarter ending Sep 30 2026, within Medical Laboratories Industry	Quick Ratio	Sep 30 2026 MRQ Cash & cash equivalent	Sep 30 2026 MRQ Current Liabilities
Miragen Therapeutics Inc	11.70	$ 955.206 Millions	$ 81.673 Millions
Billiontoone Inc	9.26	$ 561.512 Millions	$ 60.637 Millions
Absci Corp	8.70	$ 173.729 Millions	$ 19.958 Millions
Maxcyte inc	6.36	$ 101.280 Millions	$ 15.916 Millions
Personalis Inc	5.17	$ 254.841 Millions	$ 49.274 Millions
Veracyte Inc	4.40	$ 370.532 Millions	$ 84.209 Millions
Castle Biosciences Inc	4.11	$ 277.665 Millions	$ 67.612 Millions
Fulgent Genetics Inc	4.07	$ 292.739 Millions	$ 71.877 Millions
Omniab Inc	3.81	$ 64.210 Millions	$ 16.853 Millions
Guardant Health Inc	2.75	$ 1,026.848 Millions	$ 373.165 Millions
Incyte Corporation	2.68	$ 3,854.572 Millions	$ 1,437.818 Millions
Exagen Inc	2.14	$ 28.092 Millions	$ 13.100 Millions
Biodesix Inc	1.99	$ 28.409 Millions	$ 14.248 Millions
Caredx Inc	1.80	$ 250.480 Millions	$ 138.975 Millions
Butterfly Network Inc	1.80	$ 122.301 Millions	$ 67.987 Millions
Sera Prognostics Inc	1.80	$ 44.089 Millions	$ 24.527 Millions
Radnet Inc	1.11	$ 797.880 Millions	$ 716.642 Millions
Bioaffinity Technologies Inc	1.01	$ 2.550 Millions	$ 2.533 Millions

Date modified: 2026-11-07T13:19:29+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.